Azithromycin Reduction to Reach Elimination of Trachoma

Last updated: February 3, 2025
Sponsor: University of California, San Francisco
Overall Status: Active - Recruiting

Phase

4

Condition

Eyelid Inflammation

Treatment

Azithromycin

Clinical Study ID

NCT04185402
19-28923
5UG1EY030833
  • Ages > 1
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of appropriate informed consent

  • Stated willingness to comply with all study procedures

  • Live in one of the 80 communities with up to 20% prevalence of TF selected for thetrial

Exclusion

Exclusion Criteria:

  • Does not consent to participation

  • Unwilling to comply with all study procedures

  • Does not live in one of the 80 communities with up to 20% prevalence of TF selectedfor the trial

Study Design

Total Participants: 100000
Treatment Group(s): 1
Primary Treatment: Azithromycin
Phase: 4
Study Start date:
May 29, 2021
Estimated Completion Date:
October 31, 2026

Connect with a study center

  • Programme National de Santé Oculaire (PNSO)

    Niamey,
    Niger

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.